J.P. Morgan UK Leaders Conference
Logotype for GSK plc

GSK (GSK) J.P. Morgan UK Leaders Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for GSK plc

J.P. Morgan UK Leaders Conference summary

17 Nov, 2026

R&D investment and growth outlook

  • Accelerate Growth, announced in July, targets GBP 1.9bn in savings to fund R&D acceleration; 22 Phase III starts are expected by year-end 2026, versus ~7 last year and ~6 the year before.

  • Over five years, sales rose >8%, profit >13% and margin >500 bps, while R&D increased from a teen percentage of sales to just over 20%.

  • 2031 sales target remains >GBP 40bn, risk-adjusted for technical and regulatory success; oncology is the largest gap versus consensus, with B7-H3 and six launch-stage or near-approval products potential catalysts over the next 2–3 years.

  • Consensus 2031 sales estimates have risen from ~GBP 33bn to GBP 36.6bn; 2030 consensus margins have moved from 25% to 30%.

Savings and operating model

  • The GBP 1.9bn savings target is set for 2029, with 90% expected by 2028; delivery is potentially ahead of schedule, led by support-function streamlining, supply-chain changes, technology and AI.

  • Savings are intended primarily to accelerate R&D; through dolutegravir patent expiry in 2028–2030, margins are expected to remain stable or improve, with flexibility to retain savings for investment or let them flow through.

  • AI is being applied to field-force coaching and marketing-mix simulations, as well as target searches, patient and trial-site identification, vaccine-trial placement and organoid development; management described faster R&D workflows.

Business development and financial capacity

  • Business development priorities are oncology and respiratory immunology and inflammation, with more limited vaccine opportunities; focus is on validated mechanisms addressing unmet need, including efficacy or tolerability gaps.

  • Net debt to EBITDA was 1.8x pro forma at September-end, versus ~1.3x last year; further deals remain possible, typically in the $2bn–$4bn range, while cash generated from operations is guided above GBP 10bn this year at prior-year exchange rates.

  • Nuvalent assets Jemperli and neladalkib target non-small cell lung cancer; Jemperli first-line filing is expected by year-end, while neladalkib’s PDUFA date was set for November 27 and first-line opportunity is several years out.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from GSK